Explanation

Pharmacogenomic testing in psychiatry primarily assesses variants in CYP450 enzymes (particularly CYP2D6, CYP2C19, CYP3A4, and CYP1A2) that affect how patients metabolize psychiatric medications. The testing can reliably identify metabolizer phenotypes — poor metabolizers (who may experience more side effects at standard doses), ultra-rapid metabolizers (who may not achieve therapeutic levels), and intermediate or extensive metabolizers. This information can guide dosing decisions and identify medications more likely to cause adverse effects or be ineffective due to metabolic factors. However, medication response involves multiple factors beyond pharmacokinetics, including pharmacodynamic factors, epigenetics, environmental influences, and the complexity of psychiatric disorders. The PMHNP should discuss honestly: what the test measures (metabolizer status), what it cannot predict (overall treatment response with certainty), costs and insurance coverage, and that results are one clinical tool among many in treatment planning.

Key Takeaway

Pharmacogenomic testing can inform medication selection by identifying metabolizer status, but its ability to predict treatment response is evolving.